March is multiple sclerosis (MS) awareness month. According to the National Multiple Sclerosis...
KYNMOBI for the Treatment of OFF episodes in Parkinson’s Disease
KYNMOBI™ (apomorphine hydrochloride) is the first and only sublingual therapy indicated for the on-demand treatment of OFF episodes in Parkinson's disease.
NURTEC (Rimegepant) for the Acute Treatment of Migraine
NURTECTM (Rimegepant) is the only calcitonin gene-related peptide (CGRP) receptor antagonist indicated for acute treatment of migraine in adults.
Multiple sclerosis (MS) clinical trials 2017-19 analytical overview
March is multiple sclerosis (MS) awareness month. According to the National Multiple Sclerosis Society, nearly one million people are living with the disease in the US.
Zhittya gets regulatory approval in Mexico for trial of drug in PD patients
Zhittya Genesis Medicine has secured regulatory approval from Mexico's governing body COFEPRIS to test its drug in people with Parkinson's disease (PD).
AXS-05 shown to effectively manage depression symptoms
The drug was shown to regulate mood by improving the communication between brain cells and increasing levels of serotonin, noradrenaline and dopamine.
Blockbuster-to-be for depression flunks pivotal Phase III
Sage Therapeutics was aiming to enter a bigger market, through the potential launch of SAGE-217.
Rare neurological disease gene therapy gains from accelerated review
Metachromatic leukodystrophy could be the next indication to witness the impact of gene therapy.
Blood-brain barrier penetrating drug technology could be key to treating Alzheimer’s disease
The blood-brain barrier (BBB) is a protective element that restricts the movement of molecules between the bloodstream and central nervous system.